Literature DB >> 35799614

Multimorbidity patterns and risk of hospitalisation in children: A population cohort study of 3.6 million children in England, with illustrative examples from childhood cancer survivors.

Sheng-Chia Chung1, Stefanie Mueller1, Katherine Green2,3, Wai Hoong Chang1, Darren Hargrave2,3, Alvina G Lai1.   

Abstract

Background: Population-level estimates of hospitalisation risk in children are currently limited. The study aims to characterise morbidity patterns in all children, focusing on childhood cancer survivors versus children without cancer.
Methods: Employing hospital records of children aged <19 years between 1997 to 2018 in England, we characterised morbidity patterns in childhood cancer survivors compared with children without cancer. The follow-up began on the 5th anniversary of the index hospitalisation and the primary outcome was the incidence of comorbidities. Findings: We identified 3,559,439 eligible participants having 12,740,666 hospital admissions, with a mean age at study entry of 11.2 years. We identified 32,221 patients who survived for at least 5 years since their initial cancer diagnosis. During the follow-up period and within the whole population of 3.6 million children, the leading conditions for admission were (i) metabolic, endocrine, digestive renal and genitourinary conditions (84,749, 2.5%), (ii) neurological (35,833, 1.0%) and (iii) musculoskeletal or skin conditions (23,574, 0.7%), fever, acute respiratory and sepsis (22,604, 0.7%). Stratified analyses revealed that females and children from socioeconomically deprived areas had a higher cumulative incidence for morbidities requiring hospitalisation (p < 0.001). At baseline (5 years after the initial cancer diagnosis or initial hospitalisation for survivors and population comparisons, respectively), cancer survivors experienced a higher prevalence of individual conditions and multimorbidity (≥ 2 morbidities) compared with children without cancer. Cox regression analyses showed that survivors had at least a 4-fold increase in the risk of hospitalisation for conditions such as chronic eye conditions (hazard ration (HR):4.0, 95% confidence interval (CI): 3.5-4.7), fever requiring hospitalisation (HR: 4.4, 95% CI: 3.8-5.0), subsequent neoplasms (HR: 5.7, 95% CI:5.0-6.5), immunological disorders (HR: 6.5, 95% CI:4.5-9.3) and metabolic conditions (HR: 7.1, 95% CI:5.9-8.5). Interpretation: The overall morbidity burden among children was low in general; however, childhood cancer survivors experienced a higher prevalence and subsequent risk of hospitalisation for a range of morbidities. Targeted policies may be required to promote awareness on health vulnerabilities and gender disparity and to improve advocacy for healthcare in deprived communities. Funding: Wellcome Trust, National Institute for Health Research (NIHR) University College London Hospitals Biomedical Research Centre, NIHR Great Ormond Street Hospital Biomedical Research Centre and Academy of Medical Sciences. The funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report.
© 2022 The Author(s).

Entities:  

Keywords:  Child health; Childhood cancer survivors; Electronic health records; Health disparity; Hospitalisation risk; Multimorbidity

Year:  2022        PMID: 35799614      PMCID: PMC9253994          DOI: 10.1016/j.lanepe.2022.100433

Source DB:  PubMed          Journal:  Lancet Reg Health Eur        ISSN: 2666-7762


  51 in total

1.  Health care use of long-term survivors of childhood cancer: the British Childhood Cancer Survivor Study.

Authors:  Cornelia E Rebholz; Raoul C Reulen; Andrew A Toogood; Clare Frobisher; Emma R Lancashire; David L Winter; Claudia E Kuehni; Michael M Hawkins
Journal:  J Clin Oncol       Date:  2011-09-26       Impact factor: 44.544

2.  Aging and risk of severe, disabling, life-threatening, and fatal events in the childhood cancer survivor study.

Authors:  Gregory T Armstrong; Toana Kawashima; Wendy Leisenring; Kayla Stratton; Marilyn Stovall; Melissa M Hudson; Charles A Sklar; Leslie L Robison; Kevin C Oeffinger
Journal:  J Clin Oncol       Date:  2014-03-17       Impact factor: 44.544

3.  Cumulative burden of subsequent neoplasms, cardiovascular and respiratory morbidity in young people surviving cancer.

Authors:  Lesley Smith; Adam W Glaser; Darren C Greenwood; Richard G Feltbower
Journal:  Cancer Epidemiol       Date:  2020-04-09       Impact factor: 2.984

Review 4.  Pulmonary outcomes in survivors of childhood cancer: a systematic review.

Authors:  Tseng-Tien Huang; Melissa M Hudson; Dennis C Stokes; Matthew J Krasin; Sheri L Spunt; Kirsten K Ness
Journal:  Chest       Date:  2011-03-17       Impact factor: 9.410

Review 5.  Therapeutic cancer vaccines.

Authors:  Mansi Saxena; Sjoerd H van der Burg; Cornelis J M Melief; Nina Bhardwaj
Journal:  Nat Rev Cancer       Date:  2021-04-27       Impact factor: 60.716

6.  Congestive heart failure after treatment for Wilms' tumor: a report from the National Wilms' Tumor Study group.

Authors:  D M Green; Y A Grigoriev; B Nan; J R Takashima; P A Norkool; G J D'Angio; N E Breslow
Journal:  J Clin Oncol       Date:  2001-04-01       Impact factor: 44.544

7.  Long-term inpatient disease burden in the Adult Life after Childhood Cancer in Scandinavia (ALiCCS) study: A cohort study of 21,297 childhood cancer survivors.

Authors:  Sofie de Fine Licht; Kathrine Rugbjerg; Thorgerdur Gudmundsdottir; Trine G Bonnesen; Peter Haubjerg Asdahl; Anna Sällfors Holmqvist; Laura Madanat-Harjuoja; Laufey Tryggvadottir; Finn Wesenberg; Henrik Hasle; Jeanette F Winther; Jørgen H Olsen
Journal:  PLoS Med       Date:  2017-05-09       Impact factor: 11.069

8.  The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) statement.

Authors:  Eric I Benchimol; Liam Smeeth; Astrid Guttmann; Katie Harron; David Moher; Irene Petersen; Henrik T Sørensen; Erik von Elm; Sinéad M Langan
Journal:  PLoS Med       Date:  2015-10-06       Impact factor: 11.069

9.  The cumulative burden of surviving childhood cancer: an initial report from the St Jude Lifetime Cohort Study (SJLIFE).

Authors:  Nickhill Bhakta; Qi Liu; Kirsten K Ness; Malek Baassiri; Hesham Eissa; Frederick Yeo; Wassim Chemaitilly; Matthew J Ehrhardt; Johnnie Bass; Michael W Bishop; Kyla Shelton; Lu Lu; Sujuan Huang; Zhenghong Li; Eric Caron; Jennifer Lanctot; Carrie Howell; Timothy Folse; Vijaya Joshi; Daniel M Green; Daniel A Mulrooney; Gregory T Armstrong; Kevin R Krull; Tara M Brinkman; Raja B Khan; Deo K Srivastava; Melissa M Hudson; Yutaka Yasui; Leslie L Robison
Journal:  Lancet       Date:  2017-09-08       Impact factor: 79.321

10.  Factors associated with COVID-19-related death using OpenSAFELY.

Authors:  Elizabeth J Williamson; Alex J Walker; Krishnan Bhaskaran; Seb Bacon; Chris Bates; Caroline E Morton; Helen J Curtis; Amir Mehrkar; David Evans; Peter Inglesby; Jonathan Cockburn; Helen I McDonald; Brian MacKenna; Laurie Tomlinson; Ian J Douglas; Christopher T Rentsch; Rohini Mathur; Angel Y S Wong; Richard Grieve; David Harrison; Harriet Forbes; Anna Schultze; Richard Croker; John Parry; Frank Hester; Sam Harper; Rafael Perera; Stephen J W Evans; Liam Smeeth; Ben Goldacre
Journal:  Nature       Date:  2020-07-08       Impact factor: 49.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.